77591-33-4
TB-500
Actin-sequestering 43-residue peptide studied in cell migration and repair models.
Typical release98.5%
From
£58.00
In stock
Tissue Repair & RegenerativeMost ordered
BPC-157
Body protection compound 157 · PL 14736
Fifteen-residue gastric pentadecapeptide fragment studied in angiogenesis and repair models.
Total, ex VAT
£36.00
- Released at ≥ 99.0% (RP-HPLC, area %)
- Identity confirmed by ESI-MS against theoretical mass
- Batch certificate matched to the vial, verifiable online
- Same working day dispatch before 14:00, tracked
For laboratory research use only. Not for human or veterinary use, and not a medicine, food or cosmetic. Sold to qualified researchers and institutions who accept responsibility for safe handling and lawful use.
Compound data
What is in the vial
Indicative values for this line. The certificate issued with your batch is the authoritative record and reports the measured figures for the material you receive.
- CAS number
- 137525-51-0
- Molecular formula
- C62H98N16O22
- Average mass
- 1419.53 g/mol
- Sequence
- Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
- Residues
- 15
- Class
- Gastric pentadecapeptide fragment
- Form as supplied
- Lyophilised powder
- Appearance
- White to off-white lyophilised powder
- Purity specification
- ≥ 99.0% (RP-HPLC, area %)
- Solubility
- Soluble in sterile or bacteriostatic water.
- Storage
- Lyophilised: −20 °C, desiccated and dark. Reconstituted: 2–8 °C.
Targets and pathways
- VEGFR2 signalling and angiogenesis
- Nitric oxide system
- Focal adhesion / FAK-paxillin pathways
Overview
About BPC-157
BPC-157 is a fifteen-residue sequence derived from a protein found in gastric juice. It is unusually stable for an unmodified peptide — it survives in gastric acid, which is what drew attention to it — and that stability comes from its proline-rich composition rather than from any synthetic modification.
The research literature centres on angiogenesis and tissue repair, with proposed mechanisms including VEGFR2 pathway activation, nitric oxide system interaction and effects on focal adhesion complexes. Much of the primary work comes from a small number of groups, which is worth knowing when weighing the evidence base.
In short
- Fifteen residues, proline-rich, unusually acid-stable without modification
- Studied in angiogenesis, tendon, ligament and gastrointestinal repair models
- Released at ≥ 99.0% area-percent by RP-HPLC
- Available in a five-vial pack for extended study programmes
Where it is used
Research applications
Angiogenesis
VEGFR2 pathway involvement is the most-studied proposed mechanism, examined in endothelial cell and vessel formation assays.
Tendon and ligament models
Fibroblast outgrowth and collagen organisation are common endpoints in the musculoskeletal literature.
Gastrointestinal repair
Given its origin in gastric juice, mucosal integrity models remain a significant strand of work.
Handling
Reconstitution and stability
Reconstitution
Reconstitute with sterile or bacteriostatic water added slowly against the inner wall of the vial. Allow the cake to dissolve without agitation, swirling gently if required. Do not vortex or shake.
Stability
Lyophilised at −20 °C, desiccated and protected from light, stable for at least 24 months. Reconstituted and held at 2–8 °C, use within 28 days. Avoid repeated freeze-thaw.
Notes
- Bring the vial to room temperature before opening so atmospheric moisture does not condense onto cold powder.
- Record the reconstitution date on the vial; concentration drift between runs is usually evaporation, not synthesis variance.
- Aliquot at first reconstitution where the working programme needs more than a few withdrawals.
Laboratory reference
Reconstitution calculator
Enter the fill weight on the vial and the diluent volume you intend to add. The calculator returns the resulting solution concentration and the volume that contains a given mass.
- Concentration
- 2.500 mg/mL · 2500 µg/mL
- Volume containing target mass
- 100.0 µL · 0.1000 mL
Figures are mass-to-volume arithmetic for laboratory preparation of BPC-157 and take no account of net peptide content, which is stated on the batch certificate and should be applied to the fill weight before calculating. Nothing here constitutes dosing, administration or clinical guidance of any kind.
Published work
What the literature reports
Summaries of published findings, provided as research reference. These describe work done by others in preclinical and clinical settings; they are not claims about this material or outcomes for any reader.
Angiogenic mechanism
Work implicating VEGFR2 signalling in the compound's effects on endothelial cells and vessel formation.
Hsieh et al., Journal of Molecular Medicine, 2017
Tendon fibroblast studies
Reported effects on tendon fibroblast outgrowth, migration and survival in culture.
Chang et al., Journal of Applied Physiology, 2011
Questions
BPC-157 — asked and answered
Something not covered here? Ask us directly — technical questions reach someone who runs the assays.
- Which salt form is supplied?
- Acetate. Residual acetate is reported on the certificate, which matters when calculating net peptide content from gross weight.
- Is it stable in acidic conditions?
- Notably so for an unmodified peptide, which is what made it of interest. For laboratory storage the usual conditions still apply: −20 °C lyophilised, 2–8 °C in solution.
- How strong is the evidence base?
- Much of the primary literature comes from a limited number of groups. We supply material to specification; assessing the literature is the researcher's judgement.
Same class
Others in Tissue Repair & Regenerative
89030-95-5
GHK-Cu
Copper(II) complex of the Gly-His-Lys tripeptide, studied in matrix remodelling and repair.
Typical release98.4%From
£46.00
In stock
67247-12-5
KPV
The C-terminal tripeptide of α-MSH, studied for anti-inflammatory activity without pigmentation effects.
Typical release99.0%From
£28.00
In stock
Important
BPC-157 is supplied strictly for laboratory research and analytical use. It is not a medicine, food, cosmetic or veterinary product; it is not for human or animal consumption; and it is not intended to diagnose, treat, cure or prevent any condition. It is not manufactured, tested or released to any standard that would support administration to humans or animals. Information on this page is compiled for research reference and is not medical advice. No dosing, administration or therapeutic guidance is given or implied. By ordering you confirm you are a qualified researcher or institution and accept responsibility for safe handling and lawful use.